Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
Featured trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

  • 0 views
  • 19 Jun, 2022
  • 16 locations
Featured trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

  • 714 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

  • 171 views
  • 08 Dec, 2020
  • 1 location
Featured trial
Do you suffer from Hemorrhoids?

Do you suffer from Hemorrhoids?

  • 1577 views
  • 25 Mar, 2021
  • 1 location
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)

This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell

mk-3475
adjuvant therapy
cancer
pembrolizumab
  • 117 views
  • 16 Sep, 2022
  • 124 locations
Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

In this open-label, multicenter, Phase II study, the investigators propose to evaluate the efficacy of ruxolitinib, an orally administered inhibitor of JAK1/2, in solid organ transplant recipients with advanced cSCC. In a safety lead-in of 6 patients, subjects will receive ruxolitinib 15mg twice daily (BID). After 4 weeks, if dose-limiting …

  • 0 views
  • 08 Jul, 2022
  • 2 locations
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma

  • 0 views
  • 19 Jun, 2022
  • 7 locations
Phase 1 Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Cemiplimab is FDA approved for treatment of basal cell and squamous cell carcinoma of the skin as well as

  • 0 views
  • 14 Sep, 2022
  • 1 location
Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC

This clinical trial proposes to evaluate a relatively unexplored approach to treatment of squamous cell carcinoma (SCC) on the lower extremities. The strategy is to directly and specifically deliver drug to the tumor. For the proposed phase I clinical trial, the investigators will perform intralesional injections of a well characterized, …

antineoplastic
imiquimod
Accepts healthy volunteers
fluorouracil
  • 286 views
  • 12 Feb, 2022
  • 1 location
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.

skin cancer
cancer
cemiplimab
  • 19 views
  • 28 Jul, 2022
  • 69 locations